Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Lorcaserin, 10 mg Clear all

Conditions: Obesity
Interventions: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions: Lorcaserin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 2 Years and older
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Cocaine Use Disorder
Interventions: Lorcaserin, Cocaine Intravenous (IV), Placebo comparator; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Smoking Cessation
Interventions: APD356-lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 31
States / cities: Encino, California • Escondido, California • Los Alamitos, California + 27 more

Conditions: Overweight and Obesity
Interventions: Belviq, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Tobacco Use Disorder, Smoking Cessation
Interventions: Lorcaserin Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: The Mind Research Network; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Interventions: Duloxetine 60 mg qd, Lorcaserin; Drug
Lead sponsor: Southeastern Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Newnan, Georgia

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31,889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Obesity
Interventions: Lorcaserin hydrochloride; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Obesity
Interventions: Lorcaserin 10 mg BID, Matching Placebo BID; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizoaffective Disorder, Overweight
Interventions: Lorcaserin, Metformin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Chronic Weight Management
Interventions: lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more

Conditions: Obesity
Interventions: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Participants
Interventions: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cocaine Use Disorders
Interventions: Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo; Drug · Other
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 21 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cocaine Dependence
Interventions: Lorcaserin, Placebo Oral Tablet; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Overweight, Obese
Interventions: LLLT, Lorcaserin; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions: Lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 14,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 373
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more

Conditions: Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions: Lorcaserin, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Alcohol Use Disorder, Tobacco Smoking
Interventions: Lorcaserin Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: The Mind Research Network; Other
Eligibility: 21 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Opioid-use Disorder
Interventions: Lorcaserin, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine-Related Disorders, Opioid-Related Disorders
Interventions: Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo, Group B2 Parallel Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Muscle Weakness, Sepsis
Interventions: Lorcaserin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cocaine-Related Disorders
Interventions: Lorcaserin, Placebo Oral Capsule; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more

Search by objective public record fields.

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Predictors of Lorcaserin-Induced Weight Loss

Mechanisms of Lorcaserin for Smoking Cessation

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Lorcaserin Intra Venous Cocaine Effects

Rebalancing the Serotonergic System in Cocaine Dependence

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Lorcaserin in the Treatment of Cocaine Use Disorder